Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Hisse Senetlerindeki Sıralama #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Hisse Fiyatı
$0.0001
Son senkronizasyon: 2026-08-11
Piyasa Değeri
$36.84K
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-66.67%
Ülke
US
Ticaret Amarantus BioScience Holdings, Inc. (AMBS)

Kategori

Amarantus BioScience Holdings, Inc. (AMBS) için gelir
Aug 2026 itibarıyla gelir TTM: 0
Amarantus BioScience Holdings, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Amarantus BioScience Holdings, Inc. için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE